(Q34020276)

30 July 2017

Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy (English)

1 reference

chronic lymphocytic leukemia

30 July 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

5

S Pittaluga

1 reference

30 July 2017

S E M Herman

1

1 reference

30 July 2017

X Sun

2

1 reference

30 July 2017

E M McAuley

3

1 reference

30 July 2017

M M Hsieh

4

1 reference

30 July 2017

M Raffeld

6

1 reference

30 July 2017

D Liu

7

1 reference

30 July 2017

K Keyvanfar

8

1 reference

30 July 2017

C M Chapman

9

1 reference

30 July 2017

J Chen

10

1 reference

30 July 2017

J J Buggy

11

1 reference

30 July 2017

G Aue

12

1 reference

30 July 2017

J F Tisdale

13

1 reference

30 July 2017

P Pérez-Galán

14

1 reference

30 July 2017

A Wiestner

15

1 reference

30 July 2017

language of work or name

1 reference

26 April 2013

1 reference

30 July 2017

1 reference

30 July 2017

27

1 reference

30 July 2017

12

1 reference

30 July 2017

2311-2321

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2013.131

30 July 2017

0 references

cites work

Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

Nurture versus nature: the microenvironment in chronic lymphocytic leukemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

Antigens in chronic lymphocytic leukemia--implications for cell origin and leukemogenesis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia

28 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.131

Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.131

Expression and function of toll like receptors in chronic lymphocytic leukaemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.131

Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.131

The B-cell receptor signaling pathway as a therapeutic target in CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.131

Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.131

Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.131

Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.131

Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.131

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.131

A novel Rag2-/-gammac-/--xenograft model of human CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.131

Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.131

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.131

Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126654

Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status

29 October 2018

1 reference

12 December 2020

Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft model

1 reference

12 December 2020

A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease

1 reference

12 December 2020

Survival of leukemic B cells promoted by engagement of the antigen receptor

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2013.131

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference